Aptevo Therapeutics Inc. — Investor Relations & Filings
Filings indexed
683
across all filing types
Latest filing
2026-05-06
Regulatory Filings
Country
US
United States of America
Listing
US
APVO
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer. The company specializes in creating bispecific and trispecific antibody-based therapeutics designed to harness a patient's immune system to fight malignancies. Its pipeline includes multiple candidates targeting both hematologic cancers and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target various tumor antigens, including PSMA for prostate cancer and Nectin-4 for solid tumors, utilizing mechanisms like T-cell engagement and co-stimulation to enhance anti-tumor activity.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | |
| Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | |
| 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| SCHEDULE 13G/A Filing | 2026-02-17 | English | |
| 8-K Filing | 2026-02-03 | English |
Browse filings by year
11 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 42001589 | 8-K - Aptevo Therapeutics Inc. (0001671584) (Filer) | 2026-05-06 | English | ||
| 33062838 | Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | 2026-03-27 | English | ||
| 32896295 | 8-K - APTEVO THERAPEUTICS INC. (0001671584) (Filer) | 2026-02-19 | English | ||
| 31224528 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224515 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 31224508 | 8-K Filing | 2026-02-03 | English | ||
| 31224455 | 424B4 Filing | 2026-01-30 | English | ||
| 31224522 | S-1 Filing | 2026-01-28 | English | ||
| 31224517 | DEF 14A Filing | 2026-01-26 | English | ||
| 12947011 | PRE 14A | 2026-01-16 | English | ||
| 12947014 | 8-K | 2026-01-09 | English | ||
|
2025
4 filings
| |||||
| 12947015 | 8-K | 2025-12-29 | English | ||
| 12947016 | 8-K | 2025-12-09 | English | ||
| 12947017 | Regulatory Filings 2025 | 2025-11-26 | English | ||
| 12947019 | 424B4 | 2025-11-25 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
Aptevo Therapeutics Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35422/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35422 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35422 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35422 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35422}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aptevo Therapeutics Inc. (id: 35422)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.